Related Experiment Videos
[153Sm]EDTMP: a potential therapy for bone cancer pain
1Medicine Department, King/Drew Medical Center, Los Angeles, CA 90059.
Seminars in Nuclear Medicine
|January 1, 1992
Summary
Samarium-153 (153Sm) EDTMP effectively relieved pain in bone metastases patients. Further studies are needed to confirm its analgesic efficacy beyond the ligand effect.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiopharmaceutical Therapy
Background:
- Reactor-produced samarium-153 (153Sm) is a beta and gamma emitter with a 46.3-hour half-life.
- 153Sm complexed with EDTMP shows high bone localization (>50% of administered dose).
Purpose of the Study:
- To evaluate the efficacy of 153Sm-EDTMP in patients with painful bone metastases.
- To assess the safety profile, specifically myelotoxicity.
- To determine the need for further studies to exclude a ligand analgesic effect.
Main Methods:
- A therapeutic trial was conducted on patients with painful bone metastases.
- The efficacy of 153Sm-EDTMP as a pain analgesic was assessed.
- Myelotoxicity was monitored.
Main Results:
- 65.4% of evaluable patients experienced pain relief.
- Observed myelotoxicity was mild and transient.
- The study suggests potential clinical utility for 153Sm-EDTMP.
Conclusions:
- 153Sm-EDTMP demonstrates significant pain relief in patients with bone metastases.
- The treatment appears safe with manageable side effects.
- Further research is required to isolate the specific analgesic effect of 153Sm-EDTMP.